1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Musculoskeletal Pain – Pipeline Review, H1 2013

Musculoskeletal Pain – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 166 pages

Musculoskeletal Pain – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Musculoskeletal Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Musculoskeletal Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Musculoskeletal Pain. Musculoskeletal Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Musculoskeletal Pain.
- A review of the Musculoskeletal Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Musculoskeletal Pain pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Musculoskeletal Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Musculoskeletal Pain pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Musculoskeletal Pain - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Musculoskeletal Pain Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Musculoskeletal Pain 9
Musculoskeletal Pain Therapeutics under Development by Companies 11
Musculoskeletal Pain Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Pre-Clinical Stage Products 19
Comparative Analysis 19
Musculoskeletal Pain Therapeutics - Products under Development by Companies 20
Musculoskeletal Pain Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Musculoskeletal Pain Therapeutics Development 24
DURECT Corporation 24
BioDelivery Sciences International, Inc. 25
Dainippon Sumitomo Pharma Co., Ltd. 26
Zogenix, Inc. 27
Eisai Co., Ltd. 28
Meiji Holdings Co., Ltd. 29
Pfizer Inc. 30
Purdue Pharma L.P. 31
Teva Pharmaceutical Industries Limited 32
TransPharma Medical Ltd. 33
Collegium Pharmaceutical, Inc. 34
Mesoblast Ltd 35
Chelsea Therapeutics, Inc. 36
Array BioPharma Inc. 37
Futura Medical plc. 38
Theravance, Inc. 39
Newron Pharmaceuticals S.p.A. 40
e-Therapeutics plc 41
Neorphys 42
Grunenthal GmbH 43
Concert Pharmaceuticals, Inc. 44
QRxPharma Limited 45
Sosei Co. Ltd. 46
Adeona Pharmaceuticals, Inc. 47
Intellipharmaceutics International Inc. 48
SWITCH Biotech LLC 49
Viromed Co., Ltd. 50
TOKUHON Corporation 51
Troikaa Pharmaceuticals Ltd. 52
TheraQuest Biosciences, LLC 53
Biolab Farmaceutica 54
EirGen Pharma Ltd. 55
Musculoskeletal Pain - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
hydrocodone bitartrate ER - Drug Profile 62
Neo-1507 - Drug Profile 64
droxidopa - Drug Profile 65
ABT-110 - Drug Profile 68
bupivacaine Trandermal - Drug Profile 69
buprenorphine hydrochloride - Drug Profile 71
prednisone - Drug Profile 73
flupirtine maleate - Drug Profile 75
(morphine sulfate + oxycodone) CR - Drug Profile 76
Neurotropin - Drug Profile 78
Priralfinamide - Drug Profile 79
cebranopadol - Drug Profile 80
ETS-6218 - Drug Profile 82
cycloserine - Drug Profile 83
hydrocodone bitartrate ER - Drug Profile 84
(droxidopa + carbidopa) - Drug Profile 86
SWT-06101 - Drug Profile 88
SD-726 - Drug Profile 89
fluoxetine - Drug Profile 90
oxycodone ER - Drug Profile 91
diclofenac sodium - Drug Profile 92
flurbiprofen - Drug Profile 93
PG-201 - Drug Profile 94
buprenorphine hydrochloride ER - Drug Profile 95
mirtazapine - Drug Profile 96
TD-9855 - Drug Profile 97
cyclobenzaprine hydrochloride - Drug Profile 98
diclofenac sodium + eperisone - Drug Profile 99
calcitonin - Drug Profile 100
Mesenchymal Precursor Cells For Chronic Back Pain - Drug Profile 101
hydrocodone bitartrate - Drug Profile 102
C-10291 - Drug Profile 103
THA-902 - Drug Profile 104
(diclofenac sodium + thiocolchicoside) - Drug Profile 105
leconotide - Drug Profile 106
levocarnitine + piracetam - Drug Profile 107
(aceclofenac + eperisone) - Drug Profile 108
AYX-2 - Drug Profile 109
TPR-100-Rx - Drug Profile 110
infliximab - Drug Profile 111
pregabalin CR - Drug Profile 112
AR-786 - Drug Profile 113
pregabalin CR - Drug Profile 114
AKR-202 - Drug Profile 115
AKR-203 - Drug Profile 116
ART-237 - Drug Profile 117
Eir-099 - Drug Profile 118
XPG-120 - Drug Profile 119
XPG-125 - Drug Profile 120
COVSIM-89 - Drug Profile 121
Musculoskeletal Pain Therapeutics - Drug Profile Updates 122
Musculoskeletal Pain Therapeutics - Discontinued Products 148
Musculoskeletal Pain Therapeutics - Dormant Products 150
Musculoskeletal Pain - Product Development Milestones 153
Featured News and Press Releases 153
Appendix 161
Methodology 161
Coverage 161
Secondary Research 161
Primary Research 161
Expert Panel Validation 161
Contact Us 162
Disclaimer 162



List of Tables

Number of Products Under Development for Musculoskeletal Pain, H1 2013 13
Products under Development for Musculoskeletal Pain - Comparative Analysis, H1 2013 14
Number of Products under Development by Companies, H1 2013 16
Number of Products under Development by Companies, H1 2013 (Contd..1) 17
Number of Products under Development by Companies, H1 2013 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2013 19
Comparative Analysis by Late Stage Development, H1 2013 20
Comparative Analysis by Mid Clinical Stage Development, H1 2013 21
Comparative Analysis by Early Clinical Stage Development, H1 2013 22
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 23
Products under Development by Companies, H1 2013 24
Products under Development by Companies, H1 2013 (Contd..1) 25
Products under Development by Companies, H1 2013 (Contd..2) 26
Products under Investigation by Universities/Institutes, H1 2013 27
DURECT Corporation, H1 2013 28
BioDelivery Sciences International, Inc., H1 2013 29
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 30
Zogenix, Inc., H1 2013 31
Eisai Co., Ltd., H1 2013 32
Meiji Holdings Co., Ltd., H1 2013 33
Pfizer Inc., H1 2013 34
Purdue Pharma L.P., H1 2013 35
Teva Pharmaceutical Industries Limited, H1 2013 36
TransPharma Medical Ltd., H1 2013 37
Collegium Pharmaceutical, Inc., H1 2013 38
Mesoblast Ltd, H1 2013 39
Chelsea Therapeutics, Inc., H1 2013 40
Array BioPharma Inc., H1 2013 41
Futura Medical plc., H1 2013 42
Theravance, Inc., H1 2013 43
Newron Pharmaceuticals S.p.A., H1 2013 44
e-Therapeutics plc, H1 2013 45
Neorphys, H1 2013 46
Grunenthal GmbH, H1 2013 47
Concert Pharmaceuticals, Inc., H1 2013 48
QRxPharma Limited, H1 2013 49
Sosei Co. Ltd., H1 2013 50
Adeona Pharmaceuticals, Inc., H1 2013 51
Intellipharmaceutics International Inc., H1 2013 52
SWITCH Biotech LLC, H1 2013 53
Viromed Co., Ltd., H1 2013 54
TOKUHON Corporation, H1 2013 55
Troikaa Pharmaceuticals Ltd., H1 2013 56
TheraQuest Biosciences, LLC, H1 2013 57
Biolab Farmaceutica, H1 2013 58
EirGen Pharma Ltd., H1 2013 59
Assessment by Monotherapy Products, H1 2013 60
Assessment by Combination Products, H1 2013 61
Assessment by Stage and Route of Administration, H1 2013 63
Assessment by Stage and Molecule Type, H1 2013 65
Musculoskeletal Pain Therapeutics - Drug Profile Updates 126
Musculoskeletal Pain Therapeutics - Discontinued Products 152
Musculoskeletal Pain Therapeutics - Discontinued Products (Contd..1) 153
Musculoskeletal Pain Therapeutics - Dormant Products 154
Musculoskeletal Pain Therapeutics - Dormant Products (Contd..1) 155
Musculoskeletal Pain Therapeutics - Dormant Products (Contd..2) 156



List of Figures

Number of Products under Development for Musculoskeletal Pain, H1 2013 13
Products under Development for Musculoskeletal Pain - Comparative Analysis, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 19
Late Stage Products, H1 2013 20
Mid Clinical Stage Products, H1 2013 21
Early Clinical Stage Products, H1 2013 22
Pre-Clinical Stage Products, H1 2013 23
Assessment by Monotherapy Products, H1 2013 60
Assessment by Combination Products, H1 2013 61
Assessment by Route of Administration, H1 2013 62
Assessment by Stage and Route of Administration, H1 2013 63
Assessment by Molecule Type, H1 2013 64
Assessment by Stage and Molecule Type, H1 2013 65

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.